Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2018
At a glance
- Drugs INS 1007 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms Willow study
- Sponsors Insmed
- 05 Feb 2018 Status changed from not yet recruiting to recruiting.
- 15 Aug 2017 Planned End Date changed from 1 Apr 2020 to 1 Jun 2020.
- 15 Aug 2017 Planned primary completion date changed from 7 Jan 2020 to 1 Jun 2020.